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Abstract
Corticosteroids still remain the anchor drugs in therapy strategies for patients 
with inflammatory rheumatic diseases even though new drugs such as biologic 
or targeted synthetic molecules have emerged in the past years, being the most 
commonly prescribed medicines in the world due to their powerful immune-mod-
ulating properties. In this chapter, we aim to discuss the main characteristics of the 
glucocorticoids, their mechanism of action and effects on the immune system given 
the fact that they reduce the activation, proliferation, differentiation and survival 
of inflammatory cells such as macrophages and lymphocytes. Nevertheless, of great 
importance are the indications and tapering regimens, but also the adverse effects 
and various methods of monitoring the corticosteroid therapy.
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1. Introduction
The adrenal glands are composed of the medulla which secretes cathecola-
mines (adrenaline and noradrenaline) and the adrenal cortex which produces 
glucocorticoids (cortisol), mineralocorticoids such as aldosterone and andogens 
(dehydropiandrosterone) [1].
In the 1930s, steroidal hormones were isolated from the adrenal cortex 
and synthesized a years later. Several of these structures have potent anti-
inflammatory properties, but they can also have important side effects. Chemical 
analogues with improved activity and less side effects have been discovered and 
are being used for the treatment of numerous inflammatory and autoimmune 
diseases [2].
Although glucocorticoid (GC) is the preferred classification when using exog-
enous agents therapeutically, corticosteroids encompass both glucocorticoid and 
mineralocorticoid hormones, the term corticosteroid (CS) is considered synony-
mous to glucocorticoid. Commercially available synthetic GC formulations come in 
a number of chemical compositions, potencies and half-lives.
Glucocorticoids are hormones that regulate a variety of cellular functions, 
including growth, homeostasis, metabolism, cognition, and inflammation. GCs are 
one of the most commonly prescribed medicines in the world due to their powerful 
immune-modulating properties [3].
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2. History of corticosteroid discovery and development
Thomas Addison first described the disease named after him in 1855 in London, 
in which postmortem examination of patients indicated adrenal gland atrophy. 
The following year, in Paris, Charles Edouard Brown-Se’quard demonstrated that 
surgical removal of the adrenals in small animals caused muscle fatigue, respiratory 
insufficiency, cardiac problems and death within 12 hours [4, 5].
The Mayo Clinic’s Edward C. Kendall (1886–1972) and Zurich’s Tadeus 
Reichstein (1897–1996) continued their research. Edward Calvin Kendall isolated 
four steroidal compounds from adrenal extracts in 1946. He labeled them A, B, 
E, and F. Later that year, Sarett synthesized compound E, known as cortisone 
nowadays. Rheumatologist Philip Hench discovered the compound’s therapeutic 
potential in a patient with RA [6].
On April 13, 1949, the Mayo Clinic’s Proceedings of Staff Meetings confirmed 
the first therapeutic use of cortisone. The first patient, a 29-year-old married 
woman in her fourth year of rheumatoid arthritis (RA), had been chosen by Philip 
S. Hench (1896–1965), chief of the Rheumatology Section [7, 8]. Before September 
1948, when she received the first twice daily intramuscular injections of 50 mg of 
cortisone, the patient had been seen at the Mayo Clinic and had received multiple 
prescriptions on many occasions. Subjective improvement was recorded after the 
second injection. Although cortisone dosage was fluctuating between 50 mg and 
100 mg per day, depressive and aggressive ideation became more prevalent, despite 
the improving of rheumatoid symptoms by 50% [9, 10].
Thus in 1950, Hench and Kendall, along with Tadeus Reichstein, were awarded 
the Nobel Prize for Medicine and Physiology for isolating with success several 
steroid hormones from the adrenals [11].
3. Mechanisms of action
The CS exercise their effect following the passive diffusion through cellular 
membranes, attachment to specific intracellular receptors and the formation of 
a complex that will be translocated intra-nuclear and will interact directly with 
certain specific DNA sequences or with other transcription factors [12, 13].
CS can exercise their effect by genomic or nongenomic mechanisms. It takes at 
least 30 minutes for the clinical effects of a GC to appear while operating by genomic 
mechanisms. Nongenomic mechanisms, by which GCs function within minutes, 
only occur when large doses are administered, such as in pulse therapy [14].
3.1 Genomic mechanisms
The majority of glucocorticoid effects are mediated by genomic pathways, 
such as binding to the GC receptor in the target cells’ cytoplasm. Since GCs are 
lipophilic and their molecular mass is low, they can easily transit through the cell 
membrane [15, 16].
The balance of the intracellular enzyme 11-hydroxysteroid dehydrogenase 
(11–HSDs) possibly influences the sensitivity of specific tissues to GCs, in 
addition to the tissue-specific intracellular density of GC receptors. Only the 
isoform of the GC receptor, which is widely distributed in all target tissues, binds 
to GCs. The GC receptor–GC complex is activated and subsequently transported 
into the nucleus. As a dimer, it binds to sites in DNA which respond to GC, thus 
being able to control the transcription of targeted genes. This process is termed 
transactivation [17].
3
Applications of Corticosteroid Therapy in Inflammatory Rheumatic Diseases
DOI: http://dx.doi.org/10.5772/intechopen.98720
As monomers, activated GC receptor – GC complexes interact with transcrip-
tional factors (such as activator protein (AP)-1, interferon regulatory factor (IRF)-
3, and nuclear factor-κB (NF-κB)). These transcriptional factors are prevented from 
binding to their consensus sites in DNA. Transrepression is a process that results in 
the downregulation of predominantly pro-inflammatory protein synthesis [18].
The hypothesis has been proposed that side effects of GCs may be based 
predominantly on transactivation, whereas the anti-inflammatory effects can be 
attributed to transrepression.
The binding of GC to specific sites at the DNA level, can cause suppression or 
stimulation of gene transcription and numerous effects on the inflammatory process 
such as:
• attachment at the level of promoter sites of the pro-inflammatory genes and 
their inhibition (interleukin (IL)-1α, IL-1β);
• recruitment of transcription factors of gene promoter domains which encode 
the production of anti-inflammatory factors (IKBα-transcription inhibitor 
factor of NF-KB, IL-10, α-2 macroglobulin, IL-1R);
• suppression of the synthesis of most pro-inflammatory cytokines through the 
inhibition of NF-KB or AP-1, indispensable for the transcription of inflamma-
tion mediators [19].
Consequences of GC interference with the phenomenon of gene transcrip-
tion consist of: stimulation of the synthesis of angiotensin conversion enzyme 
or endopeptidases which neutralizes bradykinin, a central vasodilator peptide 
involved in the onset angioedema. Another effect is the inhibition of the synthesis 
of pro-inflammatory factors by the phagocytic cells through stimulating lipocortin 
1 synthesis and, subsequently, inhibition of phospholipase A2 which is respon-
sible for the synthesis of arachidonic acid at the level of membrane phospholipid, 
prostaglandins, leukotrienes and free oxygen radicals. Nevertheless the inhibition 
of cyclooxygenase (COX)-2 synthesis, the inducible form of COX, responsible for 
production of prostaglandins (PG) at the inflammatory site is another consequence 
of the GC interference with gene transcription [20].
3.2 Nongenomic mechanisms
In addition to genomic effects, GCs exert their effects through nongenomic 
pathways, represented by the interaction with selective membrane receptors 
(specific nongenomic effects) or directly on the biological membranes (nonspecific 
nongenomic effects).
Nongenomic effects at high doses of GCs occur much faster than genomic 
effects—within minutes. Membrane-bound GC receptors are one mechanism. 
Nongenomic actions which do not include GC receptors change cell function by 
physicochemical interactions with biologic membranes [21].
4. Effects on the immune system
One of the main function of GCs is the inhibition of the activation, prolifera-
tion, differentiation and survival of macrophages and T lymphocytes as well 
as other inflammatory cells. GCs also promote apoptosis mainly of immature 
and activated T cells. Changes in cytokine synthesis and secretion are primarily 
responsible for this activity.
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B lymphocytes and neutrophils, on the other hand, are less responsive to 
glucocorticoids, and glucocorticoid treatment can improve their survival [22].
4.1 Leukocytes and fibroblasts
The administration of GC has an effect on the circulating neutrophil granulo-
cytes, increasing their number in the peripheral blood. This results in decreased 
myelopoiesis and bone marrow release. The effects also apply to the T cells, 
resulting in their redistribution. The redistribution of lymphocytes has no clinical 
implications. This effect occurs after 4 to 6 hours of a single dose of prednisone 
and returns to normal within 24 hours. The activity of B cells and the synthesis 
of immunoglobulin are unaffected. However, the susceptibility to infection is 
increased due to the effects of GCs on monocytes and macrophages. These effects 
lead to a decrease in the expression of class II major histocompatibility complex 
(MHC) molecules and Fc receptors. The administration of GC also affects the 
fibroblasts, leading to reduced proliferation and synthesis of fibronectin and 
prostaglandins [23].
4.2 Cytokines
One of the most important effects of GC therapy in chronic inflammatory 
disorders is on cytokine synthesis and action. A wide range of cytokines are inhib-
ited by GC administration. GCs inhibit most Th1 pro-inflammatory cytokines 
such as interleukins (IL-1, IL-2, IL-3, IL-6, IL-17), but also tumor necrosis factor 
(TNF), interferon-γ and GM-CSF. These cytokines are thought to be responsible for 
synovial proliferation, cartilage damage and bone deterioration in people with RA 
[24]. GCs have controversial effects on Th2 cytokines such as IL-4, IL-10 and IL-13, 
either by stimulating or having no effect on their development [25].
4.3 Pro-inflammatory enzymes
Arachidonic acid metabolism is an essential part of the inflammatory cascade. 
An essential part of the cascade of inflammation is the development of prostaglan-
dins and leukotrienes, the majority of which are highly pro-inflammatory. GCs also 
have an effect on the inhibition of the development of COX-2 and phospholipase 
A2, induced by cytokines. This process is located in monocytes/macrophages, 
fibroblasts and endothelial cells. Furthermore, in vitro and in vivo, glucocorticoids 
promote the inhibition of the metalloproteinases, especially collagenase and 
stromelysin. These metalloproteinases are considered the key effectors of cartilage 
degradation induced by IL-1 and TNF [26].
4.4 Adhesion molecules and permeability factors
Pharmacologic doses of GCs significantly reduce plasma exudation and leu-
kocyte recruitment into inflammatory sites. Adhesion molecules regulate the 
migration of inflammatory cells into the sites of inflammation, which is essential in 
chronic inflammatory diseases.
GCs also exert their effect by stimulating the expression of adhesion molecules 
such as intercellular adhesion molecule-1 and E-selectin through the inhibition of 
pro-inflammatory cytokines. GC also have an effect on the inhibition of chemotac-
tic cytokines such as IL-8 and macrophage chemoattractant proteins which attract 
immune cells to the inflammatory site. The production of nitric oxide is increased 
in the sites with active inflammation by the pro-inflammatory cytokines, leading 
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to an increase in blood flow, exudation and likely activation of the  inflammatory 
response. GCs effectively inhibit the inducible form of nitric oxide synthase 
induced by cytokines [27].
5. Pharmacology
After administration, both orally and parenterally, absorption is rapid and 
subsequently CS bind to 90% of plasma proteins. The binding is mainly done by 
specific globulin (CBG-corticosteroid binding globulin or transcortin) and in a 
reduced percentage by albumin. The biologically active form is the free cortisol 
(10%), which achieves high concentrations in most tissues. Metabolism takes place 
in the liver and excretion is urinary.
Medicinal products included in this class are similar in absorption rate, with 
differences in half-life and intensity of anti-inflammatory effect. Depending on the 
duration of action, GC can be classified into short-, medium- or long-term.
The route of administration can be:
• parenteral - intravenous pulse therapy in doses of 1–2 g, in the activity periods 
of the disease, in patients with RA, systemic lupus erythematosus (SLE) 
vasculitis, or intramuscular;
• oral - usually in the case of chronic GC therapy;
• intra-articular with depot preparations with local action;
• topical with variable absorption rates [28].
Systemic administration of GC therapy can be done in high doses, for a short 
period, in acute situations, or chronically, with periodic dose adjustment, depend-
ing on the therapeutic response and adverse effects. Discontinuation of therapy is 
considered either when the maximum therapeutic effect has been reached or in case 
of inefficiency or severe adverse effects without response to the specific therapy [29].












Cortisone 25 0.8 No 0.5 8–12
Cortisol 20 1 Yes 1.5–2 8–12
Intermediate-acting
Methylprednisolone 4 5 No >3.5 18–36
Prednisolone 5 4 Yes 2.1–3.5 18–36
Prednisone 5 4 Yes 3.4–3.8 18–36
Triamcinolone 4 5 Yes 2–5 18–36
Long-acting
Dexamethasone 0.75 20–30 Yes 3–4.5 36–54
Betamethasone 0.6 20–30 Yes 3–5 36–54
Table 1. 
Characteristics of main GCs.
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6. Indications and dosing
Glucocorticoid therapy is indicated in multiple rheumatic diseases. In patholo-
gies such as inflammatory myopathies, polymyalgia rheumatic, but also in systemic 
vasculitis, GCs are considered the focal point of the therapeutic strategy.
On the other hand, in systemic scleroderma, GCs are contraindicated in high 
doses, due to the increased risk of scleroderma renal crisis. However, they can be of 
use when systemic sclerosis is complicated by myositis or interstitial lung disease. 
Glucocorticoids are used as an adjunctive treatment or not at all in the treatment of 
other diseases [30].
In RA, GCs exert their effects by complementing the disease-modifying anti-
rheumatic drugs (DMARDs). GCs are helpful in reducing pain in osteoarthritis, 
although they are not administered on a regular basis, with the exception of intra-
articular injections if there are symptoms of synovitis in an osteoarthritic joint.
GCs are used to treat a variety of rheumatic diseases in varying dosages. 
Standardization of dosing regimens has been suggested based on pathophysiologic 
and pharmacokinetic evidence:
• low dose - ≤ 7.5 mg prednisone equivalent per day;
• medium dose - >7.5 mg and ≤ 30 mg prednisone equivalent per day;
• high dose - > 30 mg and ≤ 100 mg prednisone equivalent per day;
• very high dose - >100 mg prednisone equivalent per day;
• pulse therapy - ≥250 mg prednisone equivalent per day for one or a few days [31].
7. Systemic adverse effects of glucocorticoid therapy
It is not surprising that glucocorticoids may have a wide range of side effects 
given their diverse pathways and sites of action. The majority of these side effects 
are unavoidable, but the risk of most complications is dose and time dependent and 
lowering GC dosage reduces the risk of complications [32].
7.1 Risk of infections
In vitro, glucocorticoids reduce neutrophil phagocytosis and bacterial destruc-
tion, but natural bactericidal and phagocytic activities are found in vivo. Monocytes 
are however more susceptible; bactericidal and fungicidal activity in vivo and in 
vitro is decreased during treatment with medium to large doses of glucocorticoids. 
These variables can have an impact on the risk of infection. Therapy with a daily 
dosage of less than 10 mg of prednisolone or its equivalent seems to have little or 
only a mild elevated risk of infection, while treatment with doses of 20 to 40 mg 
daily seems to have an increased risk of infection. However, if the dosage and dura-
tion of therapy is prolongued, the risk of infection also rises [33].
7.2 Cardiovascular adverse effects
Some glucocorticoids seem to have mineralocorticoid effects, such as decreased 
sodium and chloride excretion and increased potassium, calcium, and phosphate 
excretion. Edema, weight gain, high blood pressure and heart complications are 
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also possible side effects of this action. Reduced sodium and chloride excretion can 
result in heart failure.
Patients with inflammatory diseases have been linked to accelerated atheroscle-
rosis and increased cardiovascular risk. Cardiovascular mortality is linked to the 
length of the disorder and the use of glucocorticoids. Because of their potentially 
harmful effects on lipids, glucose tolerance, insulin production and resistance, 
blood pressure and obesity, GCs can increase cardiovascular risk [34].
In vitro, GCs were found to suppress macrophage aggregation in damaged 
arterial walls, potentially reducing the local inflammatory response. Low-dose 
glucocorticoids can also improve inflammatory disease-related dyslipidemia. 
Low-dose GCs, on the other hand, are likely to have different effects on lipids and 
other cardiovascular risk factors in inflammatory disorders than medium and large 
doses of GCs.
Thus, in addition to conventional cardiovascular risk factors such as diabetes 
mellitus, length and level of inflammatory disease involvement, and co-therapies 
such as COX-2 selective NSAIDs, moderate and high glucocorticoid doses and long 
duration of therapy seem to be the most significant cardiovascular risk factors [35].
7.3 Osteoporosis
GC therapy directly influences osteoblasts, osteocytes and osteoclasts, reducing 
the process of bone formation and accelerating bone resorption.
Glucocorticoid receptors are located exclusively in osteoblasts, not in osteoclasts, 
the proliferation of the latter being the consequence of inhibition of osteoprotegerin 
synthesis (inhibitor of osteoclast differentiation in hematopoietic cells) and stimula-
tion of RANK production, necessary for the osteoclastogenesis. High doses of GC 
also stimulate RANKL synthesis by osteoblast precursors, an event that activates 
osteoclast differentiation and the bone resorption process [36].
Other mechanisms involved are the decrease in the secretion of androgen and 
estrogen hormones, the increase in the serum level of parathormone (consequent 
to the decrease in intestinal calcium absorption and the increase in its renal 
elimination).
Suppression of the osteoformation process is mediated by accelerating the 
apoptosis of mature osteocytes and osteoblasts and the consequent inhibition of 
osteoblast proliferation. In addition, GC influences the physiological dynamics of 
parathormone secretion, antagonizes its anabolic action and inhibits the production 
of insuline-like growth factor (IGF)-1 and testosterone.
Loss of bone mass is evident from the first months of administration, especially 
in the first year, and mainly affects the trabecular bone, which associates a higher 
risk of fracture for the vertebral site. Fracture events can occur in 30–50% of 
patients and are directly related to dose, duration of administration of GCs and 
patient age.
The assessment of fracture risk in the first six months after initiation of therapy 
should include an assessment of risk factors and bone mineral density in selected 
cases and subsequently in accordance with current recommendations. Prevention 
of GC-induced osteoporosis is done by administering calcium (1000–2000 mg/day) 
and vitamin D (600–800 IU/day) [37].
7.4 Aseptic osteonecrosis
Aseptic osteonecrosis is the cause of high doses compared to the administration 
of small, long-term doses, and is rarely seen during prednisone therapy or equiva-
lent of below 20 mg/day [38].
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7.5 Myopathy
Cortisone myopathy can occur following the administration of any type of GC 
and is the consequence of the direct catabolic effect on skeletal muscles. It is clini-
cally evident in the form of proximal muscle weakness, unaccompanied by myalgias 
or changes in the serum level of muscle enzymes [39].
7.6 Gastrointestinal adverse effects
Glucocorticoids are less toxic to the upper gastrointestinal tract than NSAIDs, 
but they do raise the risk of adverse gastrointestinal events like gastritis, ulcers 
and gastrointestinal bleeding. The effect of glucocorticoids on gastrointestinal 
events is very limited. In addition to evidence of upper gastrointestinal tract 
morbidity, GCs have been linked to cases of intestinal rupture, diverticular per-
foration and pancreatitis. In rheumatology, glucocorticoids are commonly used 
in conjunction with NSAIDs and the two drugs work together to increase the risk 
of GI side effects [40].
7.7 Ocular adverse effects
Posterior subcapsular cataracts is a well-known side effect of long-term GC 
therapy. There is no safe dosage for this complication and cataract formation has 
been documented even with inhaled GC preparations. The use of glucocorticoids 
has also been linked to cortical cataracts.
Patients taking glucocorticoids can develop cataracts as well as elevated intraoc-
ular pressure, which may cause vision problems. The occurrence of frank glaucoma, 
particularly with low-dose therapy, is uncommon and usually occurs in patients 
who are genetically predisposed [41].
7.8 Endocrine and metabolic side effects
Exogenous hypercorticism (Cushing’s syndrome) is the consequence of long-
term high doses and determines the characteristic appearance by redistribution 
of adipose tissue in the chest, face (“moon facies”) and neck (“buffalo bump”), 
trunk obesity, the appearance of hirsutism, acne, increased appetite, obesity and 
subsequently the complications represented by osteoporosis, edema, hypertension, 
growth retardation in children which require dose adjustment or alternative admin-
istration - every two days.
Adrenal insufficiency may result from suppression of the hypothalamic–pitu-
itary axis and is directly proportional to dose and duration of administration. 
High-dose corticosteroids can block the suppression of ACTH release and the rapid 
onset of adrenal insufficiency in approximately 5 days, lasting up to 4–6 weeks, 
even at doses of 10–15 mg/day. Restoration of the hypothalamic–pituitary axis 
usually occurs after 9–12 months. In order to prevent hypercorticism, it is preferred 
to administer a single morning dose, the use alternative therapy every two days or 
gradual reduction of the dose.
Changes in glucose metabolism represented by increased blood sugar is a 
consequence of the stimulation of the process of hepatic neoglucogenesis, hepatic 
production and storage of glycogen and decreased peripheral glucose utilization. It 
may cause diabetes or imbalance of pre-existing diabetes. Although the “de novo” 
onset of diabetes in patients with previously normal glucose levels is relatively rare, 
the risk is increased in the presence of a family history of diabetes, old age or a 
history of gestational diabetes.
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Changes in lipid metabolism consist in stimulating the lipolysis process and 
increasing the amount of free fatty acids. The increase in insulin secretion, due to 
hyperglycemia, will cause a stimulating effect on the lipid metabolism, so that the two 
concomitant processes, lipolysis/lipogenesis, will cause the reorganization of adipose 
tissue and the appearance of the characteristic appearance of “lemon on toothpicks”.
Protein metabolism is inhibited, except for the hepatic site, with the occurrence 
of side effects, especially cutaneous, muscular or of the connective tissue [42].
7.9 Cutaneous adverse effects
The most common side effects, even at low doses, are represented by the appear-
ance of bruises and skin atrophy, due to the the acceleration of protein catabolism. 
In addition, facial erythema, hair fragility, acne and hirsutism may be present [43].
7.10 Neuropsychiatric adverse effects
The spectrum of symptoms is dependent on the dose and duration of admin-
istration and may be represented by anxiety, depression, psychosis, delirium, 
confusion, disorientation, cognitive deficits, sleep disturbances, the appearance 
of akathisia, usually of mild or moderate intensity. Psychosis is associated with the 
administration of prednisone at a dose of more than 20 mg/day over a long period 
of time and may require specific therapy, even under conditions of dose reduction. 
Behavioral disorders can range from mild euphoria to anxiety or depression in the 
case of long-term therapy [44].
8. Glucocorticoid therapy in rheumatoid arthritis
In this era of targeted treatments, therapeutic strategies, and comorbidity 
management in patients with RA, the potential role of GCs in RA is important to 
consider. Despite the fact that GC therapy was a significant clinical breakthrough 
for RA in the 1950s, the current focus is on the treatment’s drawbacks rather than 
its benefits.
The aim of RA therapies is to reduce disease activity and achieve clinical remis-
sion in the short term, but also to restrict or avoid structural damage and systemic 
manifestations in the medium term. In RA, GCs have a rather rapid onset of 
action, which allows time for the DMARDs exert their immunosuppressive effect. 
Furthermore, GCs are also considered to have a structural impact on the affected 
joints. However, clinicians tend to use them when in need of rapid symptomatic 
relief for their RA patients. Thus, the benefit-to-risk ratio of GCs is still uncertain, 
and their use in RA is still debatable [45].
The use of GCs therapy in RA is regulated by international rheumatology societ-
ies such as the European League Against Rheumatism (EULAR) and the American 
College of Rheumatology (ACR). These societies have formulated recommenda-
tions regarding the indications of GC therapy in RA.
The 2015 ACR recommendations for early and established RA state that GC 
therapy should be used in conjunction with DMARDs at the lowest possible dose 
and for short periods of time, only in disease flares. Adding GCs when starting a 
csDMARD, contrary to EULAR guidelines, is dependent on disease activity [46].
The benefit of GCs therapy was emphasized more in recent revisions of the 
EULAR recommendations for the treatment of early arthritis and RA than in previ-
ous versions. Short-term GCs therapy can be taken into consideration in the initial 
treatment strategy or subsequently if the beneficial effects of the initial strategy 
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have not been considerable, as bridging therapy when a change in DMARD being 
taken into account. Long-term use of GCs should be discouraged and GCs should be 
progressively diminished and discontinued, normally by 3 months and only in rare 
cases by 6 months [47].
These international protocols, taken together, recommend the use of GCs 
for disease flares and likely at the beginning of a new conventional synthetic 
DMARD (csDMARD), although specific guidance on dose, duration and length 
of administration protocols is not yet standardized. A dosage of less than 10 mg/
day is considered a low dose in the United States, and GCs could be tapered in 
less than 3 months, while the European threshold is 7.5 mg/day, and GCs may be 
administered in conjunction with csDMARDs for up to 6 months total, with the 
understanding that this duration is mostly expert-driven. Despite these discrepan-
cies, international recommendations stress the effectiveness of GCs while also 
recommending that they be used at the lowest cumulative dose possible due to the 
widespread understanding of potential side effects. The doses of GCs are usually 
expressed in prednisone equivalents in recommendations and studies [48].
In the CareRA trial were included patients with early RA and no negative progno-
sis signs. Subsequently, they were randomly assigned to one of two treatment arms: 
Methotrexate associated with GCs in one arm (30 mg/day prednisone tapered to 
5 mg/day in 6 weeks) and Methotrexate without the association of GCs in the other 
arm. At 16 weeks, the patients who received GCs reached Disease Activity Score in 28 
Joints (DAS28) remission more compared to the Methotrexate group (65% vs. 47%, 
p = 0.08). The rates of remission in the Methotrexate and GCs arm were also higher 
than the Methotrexate-only arm at 1 and 2 years, but not substantially [49].
The results of the BARFOT trial at ten years have been released. The study 
included 250 patients with early RA. Therapy with csDMARDs alone was compared 
to csDMARDs plus 7.5 mg/day prednisolone over the course of two years. The patients 
who recieved GCs demonstrated imporved clinical results at all time points (3, 6, 
12, 18, and 24 months). A four-year follow-up analysis showed no variations in the 
percentage of patients in remission between the two groups. The use of bDMARDs 
with and without GCs did not vary after ten years. Patients in the BARFOT cohort 
were included between 1995 and 1999, before the age of biologics, thus the proportion 
of patients who used a bDMARD was very limited (15% in either group) [50].
In 10 year follow-up of the BeSt study, published in 2016, 508 patients with early 
active RA were randomly assigned to one of four groups: a pre-determined mainte-
nance care regimen starting with Methotrexate; a group in which sulfasalazine was 
added to Methotrexate in case of therapy failure; a group following the guidelines of 
the COBRA study (Sulfasalazine, Methotrexate, and GCs initially at 60 mg/day, then 
gradually tapered to 7.5 mg/day in 6 weeks) and a group of patients who were admin-
istered Methotrexate and Infliximab from the beginning. In the initial study, the 
protocol in the COBRA trial proved to be more efficient at three months. However, at 
the 10-year follow-up, almost 50% of patients were in remission regardless of their 
initial group of randomization, making it difficult to conclude on the long-term 
beneficial effect of the GC treatment administered in the beginning [51].
The CAPRA-2, the double-blind, placebo controlled trial results were published 
in 2012. The study included 350 patients with active RA who were randomly 
assigned 2:1 to receive either modified release (MR) prednisone 5 mg or placebo 
once daily in the evening in addition to their current RA DMARD therapy for 
12 weeks. At week 12, the primary end point was to determine the number of 
patients who improved by 20% in RA signs and symptoms based on ACR guide-
lines, respectively the ACR20. Morning pain and stiffness, the 28-joint Disease 
Activity Score, and health-related quality of life were all evaluated. At week 12, the 
administration of MR prednisone in conjunction with DMARD therapy proved 
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higher response rates than the administration of placebo plus DMARD in the case 
of ACR20 (48% vs. 29%) and ACR50 (22% vs. 10%) scores. Overall, low-dose MR 
prednisone administered in concurrence with DMARD therapy lead to the improve-
ment RA signs and symptoms more quickly and significantly [52].
Results from the SEMIRA trial which included 421 patients with RA divided into 
two groups: the first group (n = 128) were assigned to the continued prednisone 
regimen while the second group (n = 131) were assigned to the tapered prednisone 
regimen. All patients received Tocilizumab for 24 weeks with or without conven-
tional synthetic DMARDs. In patients with low disease activity using Tocilizumab 
and treatment with GCs for at least 24 weeks, continuous glucocorticoid treatment 
at a dose of 5 mg per day for 24 weeks provided a safer and better solution than 
gradual reduction of glucocorticoids, although two-thirds of patients were able to 
safely reduce their GCs doses [53].
The CAMERA-II study’s post-trial follow-up results were released in 2017. The 
study group included 236 patients with RA. CAMERA-II compared the administra-
tion of Methotrexate plus 10 mg/day prednisone for two years to a Methotrexate 
and placebo group. After two years of therapy, disease activity decreased more 
in the Methotrexate-GCs arm than in the Methotrexate-placebo arm on average, 
but the variations seen in the first months continued to fade with time. Patients in 
the Methotrexate-GCs group had initiated a biological DMARD slightly less often 
than those in the Methotrexate-placebo group (31% vs. 50%) during the follow-up 
analysis, with a median follow-up of about 6.6 years.
Given these findings, there is little question whether GCs will reduce disease 
activity in RA patients, at least in the short term. It’s impossible to say if the 
therapeutic advantage of GCs will last in the short and long term. Because of their 
toxicity and limited structural impact, GCs should never be used alone and should 
always be combined with DMARDs [54].
9. Glucocorticoid therapy in connective tissue diseases
9.1 Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is one of the most severe autoimmune 
rheumatic diseases, with multisystemic involvement, with frequent flares and an 
increased risk of death. The treatment of SLE is guided by organ damage, but most 
often it is represented by a combination of hydroxychloroquine - the gold standard in 
SLE - and variable doses of corticosteroids depending on the severity of the visceral 
damage and often in combination with immunosuppressants agents. Early and 
aggressive treatment in SLE is essential for the prevention of organ damage, the 2019 
EULAR recommendations for the treatment of SLE supporting both the prevention 
of organ damage and the improvement of patients’ quality of life and their long-term 
survival [55]. Achieving remission or low disease activity is another important goal 
in SLE management. Complete remission, defined as the absence of disease activity 
in the absence of treatment with CS or immunosuppressant, is rare [56].
For the patients with active disease, CS in variable doses, in combination 
with hydroxychloroquine and sometimes with immunosuppressants agents, still 
represent the optimal management of SLE. Besides the anti-inflammatory and 
immunosuppressive effects, the side effects of CS are well known, most of them are 
time and dose dependent: osteoporosis, osteonecrosis, cataract, hyperglycemia or 
coronary heart disease. Although they produce a rapid reduction in symptoms and 
the recommendation is to reduce the doses ≤7.5 mg/day equivalent to prednisone, 
or discontinued therapy, some studies have shown adverse effects even at minimal 
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doses of cortisone [57]. Thus, it is recommended the administration of intravenous 
methylprednisolone pulse therapy (250–1000 mg/day for 3 consecutive days) 
depending on the body weight, during acute flares and also the early initiation of 
immunosuppressive agents, both having the role of initiating a lower oral dose, as 
well as a faster reduction of CS doses [58].
For skin damage, the first therapeutic line, in addition to avoiding exposure to 
UV radiation, is represented by topical CS. Oral CS can also be used, depending on 
the degree of skin damage [59].
Cardiovascular involvement in SLE is one of the main causes of death, due by 
both kidney damage, that can cause cardiovascular and cerebrovascular disorders, 
but also by the increased risk of developing atherosclerosis, a consequence of both 
chronic inflammation and the additional risk of CS [60]. In a study of a group of 
175 women with SLE, Manzi et al. identified the presence of carotid plaques in 40% 
of them, which correlated with the cumulative dose of prednisone and with the 
duration of therapy. Similar results were recorded in other studies that showed the 
relationship between prednisone and weight gain, blood pressure or a high serum 
cholesterol, correlation with sudden death or demonstration of subclinical athero-
matosis in 45% of a group of 78 Italian patients with SLE [61].
The risk of infections in SLE is caused by the activity of the disease, by severe 
leukopenia and by the administration of high doses of CS in association with immu-
nosuppressants agents. The results of a 2009 case–control study showed that the 
risk of severe infections was higher in the group of patients with prednisone 7.5 mg/
day vs. those who received a median dose of 2.5 mg/day thus demonstrating that the 
risk of developing infections increases by 12% for every mg/day.
In summary, CSs has an importnat role in SLE, but side effects, often dependent 
on dose and duration of administration, should not be overlooked. Therefore, intra-
venous pulsetherapy with methylprednisolone is preferred, with consequent faster 
reduction of oral doses, and also the combination of antimalarials and immunosup-
pressive agents in the therapeutic regimen [62].
9.2 Systemic scleroderma
In systemic scleroderma, the use of CS is controversial, due to the lack of 
response of vasculopathy and fibrosis to CS, and due to the increased risk of 
developing scleroderma renal crisis. Itchy skin, arthralgia and myalgia in early 
and very early diffuse cutaneous systemic sclerosis have been shown to respond to 
low doses of CS, thus suggesting an inflammatory skin component in these stages, 
characterized by perivascular and tissue infiltrates with monocytes, macrophages 
and CD4 + lymphocytes. Thus, the effects of CS can be beneficial in these stages, 
before the appearance of irreversible fibrotic changes. Also, doses of CS can be used 
in interstitial lung disease related to systemic scleroderma. Asthenia in scleroderma 
may have a good response to CS administration, although there are no studies on 
this. Another benefit in patients with scleroderma is increased appetite, although 
it is well known that it is considered an adverse effect of corticosteroids, in patients 
with scleroderma it may be considered a benefit [63].
One of the most serious complications of systemic scleroderma is scleroderma renal 
crisis (SRC). Risk factors for its occurrence are: diffuse cutaneous forms, positivity of 
anti-RNA polymerase III antibodies and the use of CS. The mechanisms by which CS 
can trigger SRC are given in particular by vasoconstriction caused by the stimulation 
of endogenous and exogenous catecholamines by cortisol. Thus, there is a reduction 
in the production of prostaglandins by the endothelium, thus causing vasospasm. 
There is a decrease in juxtaglomerular perfusion by reducing the secretion of prosta-
glandin E2 (PGE2) with consecutive vasoconstriction of renal arterioles [64].
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There are many studies that have shown that CS administration is a major risk 
factor for the development of SRC. Steen and Medsger in 1998 demonstrated in a 
case–control study that 36% of a group of 110 patients with SRC had received doses 
>15 mg/day equivalent of prednisone in the last 6 months [65]. Similar results were 
recorded in another studies in France - 60% of 50 patients with SRC had received 
CS with a mean duration of 2.65 months before the onset of SRC, respectively 59% 
of 64 patients with SRC in a study in UK [66, 67]. Montanelli et al. showed a 1.5% 
increased risk of developing SRC for each mg/day of prednisone administration 
[68]. The International Renal Crisis Survey has shown an increased risk of death of 
4% for each mg/day of prednisone administration [69].
In contrast, there were open-label studies, but performed on a small number of 
patients with early difuse cutaneous systemic sclerosis, who not report SRC at low 
doses of CS.
CS are still ones of the most used therapies in interstitial lung disease in sclero-
derma. In 2018, EUSTAR showed that 60% of patients with interstitial lung disease 
were treated with CS, regardless of whether or not scleroderma was in the early 
stages of the disease [70].
For cardiomyopathy in scleroderma, doses of CS <15 mg/day of the equivalent of 
prednisone, alone or in combination with cyclophosphamide, have been shown to 
have beneficial effects.
In conclusion, GC can be indicated in the early and very early stages of systemic 
scerosis, when there is mainly inflammation, without fibrosis, indicated for skin or 
musculoskeletal damage, but should be used with caution, to very low-dose and a 
short time duration, to avoid CRS [71].
9.3 Inflammatory myopathies
CS are the first-line medication in polymiositis (PM) and dermatomyositis 
(DM). Patients with myositis and lung interstitial disease require high doses of 
CS, either 1 g methylprednisolone/day in pulse therapy - 3 consecutive days with 
subsequent oral follow-up or 60 mg/day for 3–4 months with monitoring clinical 
and biological parameters. Dose reduction is generally slow, usually with 5 mg/
week. Some patients may relapse at dose reduction in these situation an immu-
nosuppressive agent such as methotrexate or azathioprine may be associated; if 
muscle damage decreases with decreasing CS doses, but skin involvement persists, 
hydroxychloroquine may be associated [72]. High doses of CS, as well as long dura-
tion of administration, can cause glucocorticoid-induced myositis, so this condition 
must be differentiated by the relaps with pain and muscle weakness. If the increase 
in CS doses worsens the symptoms means it is glucocorticoid-induced myositis. 
Although some studies show that high-dose CS improves the prognosis in both PM 
and DM, another study has shown that mortality and morbidity in both poly- and 
dermatomyositis are elevated even at high doses of CS [73].
9.4 Sjőgren’s syndrome
Sjőgren’s syndrome is an autoimmune disease, characterized by the presence of 
anti-Ro and anti-La antibodies, a mononuclear focal infiltrate of the exocrine glands 
and whose main manifestations are xerostomia and xerophthalmia. Oral CS admin-
istration in primary Sjőgren syndrome has been shown to correlate with decreased 
proinflammatory cytokine levels, but with increased anti-Ro52 and anti-Ro-60 
antibodies levels [74]. The same study did not show an increase in salivary volume 
after CS administration, in contrast to the study by Miyawaki et al. who demon-
strated that there was a significant increase in salivary volume upon initiation of 
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CS treatment, but with a reduction after 48 months of follow-up. Haldorsen et al. 
showed in a study that neither the use of hydroxychloroquine nor CS influenced 
salivary production [75].
Regarding the effects of CS in lowering autoantibodies levels, a small study in 
a group of 20 patients with Sjőgren syndrome who received low-dose of CS had 
significantly reduced levels of both anti-Ro/SSA and anti- La/SSB antibodies, 
an effect that maintained a 48-month follow-up in 5 patients from the group, 
compared to the study of Reksten et al. which showed an increase in anti-Ro52 
and anti-Ro-60 antibodies levels in patients with primary Sjogren syndrome 
treated with CS [76].
For eye involvement in Sjőgren syndrome, topical CS can also be used, but 
for a short period of time and with caution due to the increased risk of cata-
ract, glaucoma or local infections especially during the exacerbation of sicca 
keratoconjunctivitis.
For extraglandular involvement, low doses of CS may be used in combination 
with hydroxychloroquine for musculoskeletal damage, arthralgias, myalgia or high 
doses or pulsetherapy of methylprednisolon in glomerulonephritis.
In neurological impairment in Sjőgren syndrome, such as acute transverse myeli-
tis, the current treatment is an association of pulsetherapy of methylprednisolone 
with cyclophosphamide.
The role of CS alone or in combination with other immunosuppressive agents in 
the management of connective-tissue diseases is unquestionable, but it should be 
used with caution, in the lowest effective dose and for as short a period of time as 
possible to minimize the adverse effects [77].
10. Glucocorticoid therapy in systemic vasculitis
In the case active large vessel vasculitis, EULAR recommendations from 2018 
are to initiate therapy with GCs in high doses (40–60 mg/day equivalent of 
prednisone), followed by tapering of the dose in 2–3 months to 15–20 mg/day, 
if the patients is in remission, and to 7.5–10 mg/day at 6 months. Subsequently, 
after more than 1 year of CS therapy, it is recommended to maintain a dose of 
≤5 mg/day for giant cell arteritis and ≤ 10 mg/day for Takayasu arteritis and cease 
GCs therapy at 18–24 months. Therefore, for patients with no eye damage, the 
administration of 1 mg/kg/day of prednisone ≤60 mg/day causes a significant 
improvement in symptoms in 24–48 hours and a significant reduction of the 
inflammatory tests.
Decreases in dose reduction of corticosteroids are common in large vessel 
vasculitis, so in the case of minor relapses it is recommended to increase the dose of 
glucocorticoids to the last effective dose and in case of a major relapse it is recom-
mended to increase the dose to 40–60 mg/day.
In case of acute blindness or amaurosis fugax in giant cell arteritis, it is recom-
mended to administer pulse therapy with 500 mg - 1 g/day of intravenous methyl-
prednisolone for 1–3 days followed by the administration of oral GCs, at a dose of 
1 mg/kg/day, less than 60 mg/day, but the ocular damage is rarely reversible and 
loss of visual acuity may persist despite initiation of GC treatment in approximately 
10% of patients [78].
The treatment of polymyalgia rheumatica is based on the 2015 EULAR/ACR 
recommendations. It is recommended to use the lowest effective GC dose of 
12.5–25 mg/day equivalent of prednisone. It is necessary to individualize the dose 
reduction according to the clinical and biological profile of each patient. The 
 following dose reduction principles are recommended:
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• initial decrease - to 10 mg/day equivalent of prednisone in 4–8 weeks;
• relapse therapy - increasing the dose of glucocorticoids to the dose before relapse 
and gradually decreasing it in 4–8 weeks until the dose at which the relapse 
occurred;
• dose reduction in case of remission - the dose of prednisone is reduced by 
1 mg every 4 weeks until discontinuation of therapy, as long as remission is 
maintained [79].
The therapeutic approach in polyarteritis nodosa patients with a five factor score 
(FFS) of 0 is the use of GCs in monotherapy. The doses used are pulse therapy with 
500–1000 mg methylprednisolone/day for 3–5 days followed by 1 mg/kg/day of oral 
equivalent of prednisone in order to obtain remission, with the subsequent progres-
sive decrease of doses. In the presence of severe organ damage, cyclophosphamide 
in combination with GCs is recommended in patients with FFS ≥ 1. The recom-
mended doses are 2 mg/kgc/day orally or the administration of intravenous therapy 
of 600 mg/m2 at intervals of 2–4 weeks, for 3–6 months [80].
In ANCA-associated vasculitis, the EULAR/ERA-EDTA recommendations state 
that GCs should be administered in doses of 1 mg/kg/day of equivalent of predni-
sone or in pulse therapy with methylprednisolone 1 g/day for 3 consecutive days 
to induce remission associated with cyclophosphamide or rituximab. The target 
is to reduce the dose to 7.5–10 mg/day equivalent of prednisone after 3 months of 
treatment. To induce remission in limited forms without severe organ damage, the 
use of methotrexate in doses of 20–25 mg/week or mycophenolate mofetil in doses 
of 2–3 g/day in combination with GCs is recommended [81].
In the case of Behçet’s disease, the treatment is based on the EULAR recom-
mendations of 2018. Thus, arterial lesions benefit from treatment with GCs in 
high doses, pulse therapy with 1 g/day methylprednisolone for 3 days, followed by 
of 1 mg/kg/day equivalent of prednisone and intravenous cyclophosphamide in 
monthly courses, if no surgery is required.
In the case of neurological manifestations, depending on the severity of the 
clinical manifestations, pulse therapy with GC in doses of 1 g/day is administered 
for 7 days, followed by oral prednisone at doses of 1 mg/kgc/day for one month and 
slow dose reduction by 5–10 mg every 10–15 days.
Ocular involvement benefits from topical treatment with GC or for the rapid 
suppression of episodes of acute inflammation of high doses of systemic GC. In the 
case of refractory cutaneous and mucosal manifestations, low doses of oral GC may 
be used [82].
11.  Corticosteroids in local injections for inflammatory rheumatic 
disease
Injection therapy using corticosteroids in the local treatment of multiple mus-
culoskeletal disorders has been used with success for already more than 70 years, 
nevertheless, only a few studies of its application in joint and periarticular lesions 
based on expert opinion and outcome measures in rheumatology define efficacy 
and compare local injection of corticosteroids with other treatments.
Several controversies regarding the local mechanism of action in rheumatic 
conditions, dosing regimen, volume, which type of steroid, injection technique, 
optimal schedule of injecting or for how long, blind or ultrasound guided place-
ment of injection have arose as most of these aspects are non-standardized.
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A decade after the first systemic use of steroid drugs, Hollander, in the USA 
reported the first documented use of hydrocortisone intra-articular injections for 
arthritis [83].
The rationale for injecting corticosteroids has become apparent after analyzing 
side effects generated by their systemic administration. Several mechanisms of 
action and pharmacological effects are proposed when injected into the joints and 
soft tissues, but the premise is that injecting insoluble corticosteroid suspensions in 
limited quantities, in contact with inflamed tissues will determine the up taking of 
the active drug by the synovial cells, before being absorbed in lesser amount in the 
blood and cleared, thus reducing the systemic effects [84].
The major effect when used in intra and periarticular injections is that of 
suppressing inflammation in inflammatory rheumatic diseases such as rheumatoid 
arthritis, ankylosing spondylitis, psoriatic arthritis or gout. As in systemic adminis-
tration they exert these effects mostly by modulating the transcription of multiple 
genes, acting by binding on nuclear steroid receptors in order to regulate the rate 
of synthesis of mRNA and proteins, subsequently reducing the production of 
pro-inflammatory cytokines [85]. Administration of steroids can be done intra-
articular, in the synovial sheath of tendons for tenosynovitis, for dactilitis, bursitis 
or entesitis.
Another indication for injecting local steroids is suppression of inflammatory 
flares in degenerative joint disease, although benefits over disadvantages are still 
subject of debate. The risk of infection, Charcot-like arthritis, aseptic osteonecrosis 
or cartilage loss through altered protein synthesis may overweight the favorable 
response of pain and inflammation. Still, studies sustain major improvement of 
pain and inflammation in osteoarthritis of the knee after local injection of corti-
costeroids (triamcinolone hexacetonide) compared to placebo, persistent for up 
to six weeks after administration. Improvement may be due also to the benefits of 
joint aspiration of pathological fluid. A review of intra-articular corticosteroid for 
knee osteoarthritis in terms of pain, physical function, quality of life and safety, 
that searched the Cochrane Central Register of Controlled Trials (CENTRAL), 
MEDLINE, and EMBASE (from inception to 3 February 2015), including 27 trials 
with 1767 participants identified that intra-articular corticosteroids appeared to be 
more beneficial in pain reduction than control interventions (SMD -0.40, 95% CI 
-0.58 to −0.22). In terms of follow up benefits were moderate at 1 to 2 weeks after 
end of treatment (SMD -0.48, 95% CI -0.70 to −0.27), small to moderate at 4 to 
6 weeks (SMD -0.41, 95% CI -0.61 to −0.21), small at 13 weeks (SMD -0.22, 95% CI 
-0.44 to 0.00), and no evidence of an effect at 26 weeks (SMD -0.07, 95% CI -0.25 
to 0.11). Corticosteroids have showed to be more effective also in function improve-
ment than control interventions (SMD -0.33, 95% CI -0.56 to - 0.09), while no 
evidence has been proved of an effect of corticosteroids on quality of life compared 
to control (SMD -0.01, 95% CI -0.30 to 0.28, I2 = 0%). Patients with corticosteroid 
injections were 11% less likely to experience adverse events, 67% less likely to 
withdraw because of adverse events, and 27% less likely to experience any serious 
adverse event, but confidence intervals were wide and included the null effect.
There is little evidence to support another rationale for using local corticoste-
roids such as the clivage of the inflammatory damage – repair – damage cycle that 
mentaines a continuous low-grade inflammatory response by inhibiting tissue 
repair and scarr formation in favor of adhesion formation [86].
Several studies support a direct protective effect on the cartilage metabolism 
through promotion of articular surfactant production and not related to the anti-
inflammatory effect of corticosteroids [87].
Corticosteroids used for intra-articular injections differ in terms of potency 
and time of action, solubility playing an important role in choosing the best drug 
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according to indication. The most frequently used corticosteroid for local adminis-
tration are illustrated in Table 2.
Local side effects of injectable corticosteroids may occur when injected too 
often or when the volume and dose are not adjusted to the anatomy of the joint, 
as well as when injecting the enthesis of the tendons with large quantities of 
corticosteroids.
Joint infection is one of the most severe local adverse effects that is most likely 
to occur between 4 days and 3 weeks after the procedure, usually in a immuno-
compromised patient or with high risk of infections such as diabetics, or patients 
with joint arthroplasties or intravenous lines [88]. After injecting periarticular soft 
tissues local infection and osteomyelitis may be suggested by increasing pain, local 
swelling, fever or systemic signs of infection.
Synovial and subcutaneous tissue irritation or postinjection flare usually happens 
after soft tissue injection and is caused by the rapid intracellular ingestion of the 
microcrystalline steroid ester, more frequent after methylprednisolone with pain 
and swelling that may mimic and should be differentiated from sepsis. Pain, swell-
ing, limited range of motion and stiffness suggests transient synovitis after joint 
injection. Not only the steroid itself may cause a postinjection flare, but preserva-
tives such as parabens may be incriminated in te appearance of a local irritative 
reaction [89].
Steroid arthropathy is mostly linked to frecquent number of corticosteroid 
injections with reports of Charcot-like joint distruction after osteoarthritic hip 
injection, with conflicting evidence over the risk due to corticosteroids or rather 
to the disease progression itself [90]. Most reports support the rather chondropro-
tective effect of steroids than chondrolitic, while repeating steroid injections no 
sooner than 3 months seems to be safe over a period of 2 years [91].
Prolonged bleedeng at the procedural site or bruising may occur in patients tak-
ing anticoagulants, vasodilators, aspirin or NSAIDs with significant antiplatelet 
activity. Anticoagulation within a therapeutical INR does not contraindicate joint 
injection of corticosteroids.
Skin depigmentation is mostly due to injecting superficial lesions or when drug 
refluates back through the needle tract after retraction, mostly in dark-skinned 
patients. Of more interest is local atrophy of skin and subcutaneous tissue that may 
appear as late as one to four months after injection bu. usually dissapears in six 
months to two years [92]. Also, steroid “chalk” or “paste” deposits after substance 
flocculation may be detected through surgery at the level of previously injected 
joints and tendons [93], as well as soft tissue calcifications.
Injecting corticosteroids into tendons associated with tendon rupture or atrophy is 
widely accepted although not well supported from studies [94]. Adjusting the dose 
and the volume injected, avoiding injecting enthesis or using peppering technique 
may minimise the risks (Figure 1).
Duration of action Drug Equivalent of prednisone
Short-acting Hydrocortisone acetate 5 mg
Intermediate-acting Methylprednisolone acetate 50 mg
Triamcinolone acetonide 50 mg
Triamcinolone hexacetonide 25 mg
Long-acting Betamethasone sodium phosphate 50 mg
Table 2. 
Corticosteroids frequently used for local administration.
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More rare side effects are linked mostly to the injecting technique or expertise, 
such as nerve damage when needling a nerve, transient paresis or needle fracture [95].
12. Conclusions
Corticosteroids still remain the anchor drugs in therapy strategies in inflam-
matory rheumatic diseases even though new drugs such as biologic or targeted 
synthetic molecules have emerged in the past years. In diseases such as systemic 
vasculitis, some of the connective tissue diseases such as SLE and poly/dermato-
myositis GCs are considered the first-line therapy. Thus, it is of great importance to 
acknowledge the use of GCs in rheumatology.
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Figure 1. 
(A) Aspiration of a Baker cyst guided by ultrasound. (B) Hyperechoic images consistant of steroid deposits 
after injection.
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